We are live on ! Find out more
TA

Tamarack Advisers Portfolio holdings

AUM $2.12M
1-Year Est. Return 58.09%
This Fund
S&P 500
This Quarter Est. Return
+11.58%
1 Year Est. Return
-58.09%
3 Year Est. Return
-46.51%
5 Year Est. Return
+44.44%
10 Year Est. Return
–
AUM
$194M
AUM Growth
+$23.9M
Cap. Flow
+$19.5M
Cap. Flow %
10.02%
Top 10 Hldgs %
62.83%
Holding
53
New
7
Increased
16
Reduced
10
Closed
17

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$5.65M
2
NEOG icon
Neogen
NEOG
+$3.56M
3
ASND icon
Ascendis Pharma A/S
ASND
+$3.48M
4
VTRS icon
Viatris
VTRS
+$3.4M
5
INMD icon
InMode
INMD
+$3.13M

Top Sells

Rank Stock Value
1
PRGO icon
Perrigo
PRGO
+$9.09M
2
LNTH icon
Lantheus
LNTH
+$6.35M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$6.02M
4
CI icon
Cigna
CI
+$5.55M
5
BVS icon
Bioventus
BVS
+$5.25M

Sector Composition

Rank Sector Weight
1 Healthcare 69%
2 Consumer Staples 1.39%
3 Technology 0.82%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ATRC icon
26
AtriCure
ATRC
$1.92B
$2.22M 1.14%
50,000
-17,500
-26% -$731K
IRWD icon
27
Ironwood Pharmaceuticals
IRWD
$696M
$2.17M 1.12%
+175,000
New +$1.99M
FENC icon
28
Fennec Pharmaceuticals
FENC
$332M
$2.04M 1.05%
213,000
+38,000
+22% +$336K
RDNT icon
29
RadNet
RDNT
$5.02B
$1.88M 0.97%
100,000
+40,000
+67% +$748K
PLXS icon
30
Plexus
PLXS
$6.72B
$1.6M 0.82%
15,500
-4,500
-23% -$455K
ICUI icon
31
ICU Medical
ICUI
$4.21B
$787K 0.41%
5,000
-10,000
-67% -$1.52M
SLGC
32
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$628K 0.32%
250,000
-50,000
-17% -$140K
MXCT icon
33
MaxCyte
MXCT
$112M
$546K 0.28%
100,000
+17,901
+22% +$110K
CDNA icon
34
CareDx
CDNA
$2.26B
$342K 0.18%
30,000
+5,000
+20% +$74.1K
NSTG
35
DELISTED
NanoString Technologies, Inc.
NSTG
$239K 0.12%
+30,000
New +$260K
SLGC
36
CALL
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$50.2K 0.03%
+20,000
New +$55.8K
BIO icon
37
Bio-Rad Laboratories Class A
BIO
$8.71B
– –
-2,000
Closed -$834K
BMRN icon
38
BioMarin Pharmaceuticals
BMRN
$11.6B
– –
-71,000
Closed -$6.02M
BVS icon
39
Bioventus
BVS
$892M
– –
-750,001
Closed -$5.25M
CI icon
40
Cigna
CI
$73.7B
– –
-20,000
Closed -$5.55M
CVS icon
41
CVS Health
CVS
$133B
– –
-50,000
Closed -$4.77M
IQV icon
42
IQVIA
IQV
$38.7B
– –
-10,000
Closed -$1.81M
JAZZ icon
43
Jazz Pharmaceuticals
JAZZ
$15.9B
– –
-30,000
Closed -$4M
MOH icon
44
Molina Healthcare
MOH
$10.2B
– –
-6,000
Closed -$1.98M
NVST icon
45
Envista
NVST
$4.44B
– –
-25,000
Closed -$820K
OEF icon
46
CALL
iShares S&P 100 ETF
OEF
$20.1B
– –
-4,000
Closed -$76K
PRGO icon
47
Perrigo
PRGO
$1.4B
– –
-255,000
Closed -$9.09M
VTRS icon
48
CALL
Viatris
VTRS
$20.4B
– –
-4,000
Closed -$30K
DMTK
49
DELISTED
DermTech, Inc. Common Stock
DMTK
– –
-175,000
Closed -$693K
SLGCW
50
DELISTED
SomaLogic, Inc. Warrant
SLGCW
– –
-20,000
Closed -$9K
1
2
3

Similar funds

SCM
SevenOneSeven Capital Management Lancaster, Pennsylvania $2.17M AUM 8.67% 1-Year Est. Return
LBC
Lawrence B. Cohen $2.06M AUM 34.47% 1-Year Est. Return
ICM
ISZO Capital Management New York $2M AUM 35.61% 1-Year Est. Return
LCMP
Linse Capital Management PR San Juan, Puerto Rico $2.31M AUM
GIP
General Industrial Partners London, United Kingdom $2.57M AUM
STC
Sarah T. Connolly $1.11M AUM 24.13% 1-Year Est. Return
GC
Gilfoyle & Co San Francisco, California $671K AUM
DU
Delphia (USA) Toronto, Ontario, Canada $445K AUM 28.82% 1-Year Est. Return

Tamarack Advisers's Q4 2022 Portfolio in Review

As of Q4 2022, Tamarack Advisers held 53 positions worth $194M, up 14% from $170M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Tamarack Advisers deployed $19.5M of net new capital in Q4 2022, opening 7 new positions and adding to 16 existing holdings. Its largest new stake was Biogen: 20,000 shares worth $5.54M.

By sector, the portfolio is most concentrated in Healthcare at 69% of assets, down from 96% a quarter earlier, followed by Consumer Staples and Technology.

On the sell side, the largest reduction was Lantheus, an estimated $6.35M trimmed.

  • Tamarack Advisers's largest Q4 2022 buy was Biogen: 20,000 shares worth $5.54M.
  • Tamarack Advisers added most to Ascendis Pharma A/S in Q4 2022, an estimated $3.48M increase.
  • Tamarack Advisers's biggest Q4 2022 reduction was Lantheus, cutting an estimated $6.35M.
  • Tamarack Advisers fully exited Perrigo in Q4 2022, selling an estimated $9.09M.
  • Tamarack Advisers's ten largest holdings make up 63% of its $194M portfolio in Q4 2022.
  • Tamarack Advisers opened 7 new positions and closed 17 in Q4 2022.
  • Tamarack Advisers's portfolio value rose 14% quarter-over-quarter to $194M.

Based on Tamarack Advisers's 13F filing for Q4 2022, filed 13 Feb 2023.